Supplemental Figure 1.

siRNA	PERCENT REDUCTION	WESTERN BLOT CONT siRNA
Rac 1	45.3 ± 5.1 (4) *	
Rac 2	45.8 ± 5.6 (5) *	
PKA	26.5 ± 5.9 (6) *	
PKG	22.8 ± 3.8 (6) *	
VASP (SC)	40.1 ± 11.8(4)*	
VASP (TS)	46.3 ± 5.8 (3)*	

Supplemental - Figure 1. Reduction in specified protein in neutrophils incubated with siRNA assessed by Western blot. Cells were incubated for 20 hours with siRNA and data show the difference in protein content versus cell samples incubated with control, scrambled sequence siRNA that will not lead to specific degradation of any known cellular mRNA (labeled CONT). Western blot column shows typical results with 25 μg cell lysate protein loaded per lane. Two different siRNA sources were used in VASP experiments, Santa Cruz (SC) and Thermo Scientific (TS). Data are mean ± SE, n=number of studies with cells incubated with different siRNA species, *$p<0.05$ versus cells incubated with control siRNA.

Supplemental Table 1. ***Ex vivo*** **pyrene actin polymerization (rate/min x 10^2).**

	G-actin		SNO-actin	
	+ PBS	+ VASP	+ PBS	+ VASP
25 mM KCl	0.017 ± 0.017	0.288 ± 0.072*	0.633 ± 0.186*	0.700 ± 0.152*
50 mM KCl	0.00 ± 0.00	0.100 ± 0.001*	0.275 ± 0.048*	0.407 ± 0.088*

Fluorescence was measured as described in Methods after 1 μM pyrene G-actin was added to solutions containing 25 mM KCl or 50 mM KCl in 5 mM Tris-HCl. Solutions labeled at the top of the figure as 'G-actin' contained 8 μM skeletal muscle G-actin, those labeled 'SNO-actin' contained 5 μM skeletal muscle G-actin and 3 μM SNO-actin. Where indicated samples also contained 0.25 μM VASP. Within each buffer group, the symbol * indicates significantly different from PBS value of the G-actin sample. The SNO-actin values + PBS or VASP are not significantly different from each other. Data are mean ±SE, n=4 in all groups.